Trials / Completed
CompletedNCT05322473
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- MoonLake Immunotherapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonelokimab (M1095) | randomized treatment; parallel-group |
| DRUG | Adalimumab | randomized treatment; parallel-group |
| OTHER | Placebo | randomized treatment; parallel-group |
Timeline
- Start date
- 2022-04-25
- Primary completion
- 2023-05-09
- Completion
- 2023-08-30
- First posted
- 2022-04-11
- Last updated
- 2024-05-03
Locations
57 sites across 7 countries: United States, Bulgaria, Canada, Germany, Ireland, Netherlands, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05322473. Inclusion in this directory is not an endorsement.